1. Home
  2. HTCR vs QUCY Comparison

HTCR vs QUCY Comparison

Compare HTCR & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

HOLD

Current Price

$3.30

Market Cap

6.5M

Sector

Technology

ML Signal

HOLD

Logo Mainz Biomed N.V. Ordinary Shares

QUCY

Mainz Biomed N.V. Ordinary Shares

N/A

Current Price

$0.65

Market Cap

5.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HTCR
QUCY
Founded
2009
2008
Country
Japan
Germany
Employees
N/A
13
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
5.9M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
HTCR
QUCY
Price
$3.30
$0.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
218.6K
229.2K
Earning Date
05-14-2026
03-31-2026
Dividend Yield
81.76%
N/A
EPS Growth
414.29
N/A
EPS
0.22
N/A
Revenue
$30,407,229.00
N/A
Revenue This Year
N/A
$74.34
Revenue Next Year
$3.52
$171.48
P/E Ratio
$14.45
N/A
Revenue Growth
39.19
N/A
52 Week Low
$0.15
$0.40
52 Week High
$3.97
$0.74

Technical Indicators

Market Signals
Indicator
HTCR
QUCY
Relative Strength Index (RSI) 74.09 50.87
Support Level $0.42 $0.42
Resistance Level $3.97 N/A
Average True Range (ATR) 0.26 0.05
MACD 0.28 0.01
Stochastic Oscillator 82.19 99.95

Price Performance

Historical Comparison
HTCR
QUCY

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

About QUCY Mainz Biomed N.V. Ordinary Shares

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: